{
    "medicine_id": "b4120606b6d4a67c69861f10812c3d87c4d6abdf",
    "platform_id": "DB11635",
    "metadata": {
        "name": "Aquasol E Tpgs Liquid 77iu ml 50 mg mL Solution",
        "composition": "50 mg mL Tocofersolan",
        "clinical_particulars": {
            "therapeutic_indications": "Tocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth full term newborns up to 18 years of age L2371",
            "contraindications": {
                "disease": "7 g kg Rat L2382 Common adverse reactions The most commonly reported adverse reaction during treatment is diarrhea L2371 High doses of Vitamin E may cause diarrhea abdominal pain and other gastrointestinal conditions In the case of an overdose symptomatic treatment should be provided L2371 High doses of vitamin E have been reported to increase bleeding tendency in patients with Vitamin K deficiency or patients taking oral anti vitamins K treatment L2371 Therefore careful monitoring of the prothrombin time and international normalized ratio INR are advised A possible adjustment of the dose of oral anticoagulant during and after treatment with Vedrop may be necessary L2371 Renal impairment Data regarding patients with renal impairment are limited this drug should be administered with caution and those with renal impairment or dehydration should be closely followed L2371 Hepatic impairment This drug should be administered with caution in patients with liver impairment and under close monitoring of the liver function tests in such patients L2371 Hypersensitivity Vedrop the commercial form contains sodium methyl parahydroxybenzoate E219 and sodium ethyl parahydroxybenzoate E215 which may cause allergic reactions which are sometimes delayed L2371 Pregnancy There is no current data on taking tocofersolan during pregnancy Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy embryonal fetal development parturition or postnatal development Caution should be taken when prescribing this medication to pregnant women L2371 Breast feeding It is unknown whether tocofersolan is released into human breast milk The excretion of tocofersolan in milk has not been studied in animals L2371 Fertility No data is available L2371",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Because of its increased solubility L2374 L2376 L2380 this medication readily penetrates cells unlike other types of vitamin E MSDS which are strictly fat soluble MSDS Specific to cholestasis tocofersolan normalizes vitamin E levels relieving the symptoms of deficiency because of its facilitation of vitamin E absorption L2371 L2379",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB01083",
                        "description": "Orlistat can cause a decrease in the absorption of Tocofersolan resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "The serum concentration of Tocofersolan can be decreased when it is combined with Pitolisant"
                    },
                    {
                        "drugbank-id": "DB09046",
                        "description": "The metabolism of Tocofersolan can be increased when combined with Metreleptin"
                    },
                    {
                        "drugbank-id": "DB06119",
                        "description": "The serum concentration of Tocofersolan can be decreased when it is combined with Cenobamate"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The serum concentration of Tocofersolan can be increased when it is combined with Ritonavir"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The serum concentration of Haloperidol can be increased when it is combined with Tocofersolan"
                    },
                    {
                        "drugbank-id": "DB11652",
                        "description": "The metabolism of Tucatinib can be decreased when combined with Tocofersolan"
                    },
                    {
                        "drugbank-id": "DB11932",
                        "description": "The serum concentration of Tocofersolan can be increased when it is combined with Abametapir"
                    },
                    {
                        "drugbank-id": "DB15762",
                        "description": "The serum concentration of Tocofersolan can be decreased when it is combined with Satralizumab"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}